Patients on Simponi (golimumab) should receive the inactivated influenza vaccine annually, NOT the live attenuated intranasal vaccine.
Patients taking Simponi must avoid live vaccines, including the intranasal flu vaccine (LAIV), due to the risk of disseminated infection from the live attenuated virus. The FDA label for Simponi explicitly states to "avoid live vaccines in patients treated with SIMPONI ARIA" and warns that "use of live vaccines could result in clinical infections, including disseminated infections" 1.
Vaccine Type Selection
Use only the inactivated influenza vaccine (injection) for patients on golimumab or any TNF-blocker therapy. Multiple authoritative guidelines consistently contraindicate live attenuated vaccines in immunosuppressed patients:
- ACIP guidelines specify that persons "with known or suspected immunodeficiency diseases or who are receiving immunosuppressive therapies" should not receive LAIV 2, 3, 4, 2
- The 2014 IDSA guideline for immunocompromised hosts states that "live vaccines should not be given to immunocompromised persons" with rare exceptions that do not include TNF-blocker recipients 5
- The 2020 EULAR recommendations for vaccination in autoimmune inflammatory rheumatic diseases confirm this approach 6
Timing and Administration
Administer the inactivated influenza vaccine annually, ideally before the influenza season begins (October-November). The vaccine can be given at any point during Simponi therapy, though:
- Preferably vaccinate during quiescent disease when possible 6
- If feasible, vaccinate before starting immunosuppression for optimal response, though this is often not practical for patients already on therapy 5
- Do not delay vaccination waiting for "optimal" timing—protection from vaccination outweighs concerns about potentially reduced immunogenicity 6, 7
Expected Vaccine Response
Patients on TNF-blockers like Simponi will likely have reduced antibody responses compared to healthy individuals, but vaccination still provides meaningful clinical protection. Research confirms that while immunogenicity is diminished in immunocompromised patients, significant clinical protection from influenza complications is still achieved 8. Consider high-dose or adjuvanted inactivated influenza vaccines if available, as these may enhance immunogenicity in immunosuppressed patients 7.
Safety Considerations
The inactivated influenza vaccine is safe in patients on Simponi. It cannot cause influenza infection because it contains killed virus 9, 10. Common side effects are limited to local injection site reactions and mild systemic symptoms like myalgias or low-grade fever, which are self-limited 2.
Household Contacts
Household members and close contacts can receive either the inactivated or live attenuated influenza vaccine 3, 11, 5. While inactivated vaccine is theoretically preferred to eliminate any risk of vaccine virus transmission, if only LAIV is available, household contacts should still be vaccinated. The risk of transmission of vaccine-strain virus is theoretical and likely very low 12. If household contacts receive LAIV, emphasize good hand hygiene and minimize contact with respiratory secretions 12.
Common Pitfalls to Avoid
- Do not give the intranasal FluMist (LAIV) to patients on Simponi under any circumstances
- Do not delay vaccination waiting for disease remission or optimal immunosuppression timing
- Do not withhold vaccination from household contacts—they should be vaccinated to create a protective barrier around the immunocompromised patient
- Do not assume prior vaccination eliminates the need for annual revaccination—influenza strains change yearly and immunity wanes